JZP-110 + Placebo

Phase 2Completed
0 watching 0 views this week Active
49
Hype Score

Development Stage

Pre-clinical
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Narcolepsy

Conditions

Narcolepsy, Excessive Sleepiness

Trial Timeline

Jun 1, 2016 → May 19, 2019

About JZP-110 + Placebo

JZP-110 + Placebo is a phase 2 stage product being developed by Jazz Pharmaceuticals for Narcolepsy. The current trial status is completed. This product is registered under clinical trial identifier NCT02806908. Target conditions include Narcolepsy, Excessive Sleepiness.

Hype Score Breakdown

Clinical
17
Activity
12
Company
7
Novelty
5
Community
5

Clinical Trials (2)

NCT IDPhaseStatus
NCT02806895Phase 2Completed
NCT02806908Phase 2Completed

Competing Products

20 competing products in Narcolepsy

See all competitors
ProductCompanyStageHype Score
E2086 + E2086 Placebo + Active Comparator + Active Comparator PlaceboEisaiPhase 1
33
MK-6552 + PlaceboMerckPhase 1
33
Sodium Oxybate (Xyrem)UCBPhase 1
30
ADX-N05 + PlaceboJazz PharmaceuticalsPhase 2
49
XyremJazz PharmaceuticalsPhase 3
74
JZP258Jazz PharmaceuticalsApproved
82
ADX-N05 + PlaceboJazz PharmaceuticalsPhase 2
49
Xyrem (sodium oxybate) oral solutionJazz PharmaceuticalsPhase 3
74
JZP-258Jazz PharmaceuticalsApproved
82
JZP441 + Matching PlaceboJazz PharmaceuticalsPhase 1
30
Xyrem + Xyrem Placebo + Modafinil at established dose + Modafinil (Placebo)Jazz PharmaceuticalsPhase 3
74
JZP-110 + Placebo oral tabletJazz PharmaceuticalsPhase 3
74
JZP-258Jazz PharmaceuticalsPhase 3
74
Transition from Xyrem to XywavJazz PharmaceuticalsPre-clinical
20
JZP-110Jazz PharmaceuticalsPhase 3
74
Sunosi (solriamfetol) + Other prescription wake-promoting medications or stimulantsAxsome TherapeuticsPre-clinical
20
AXS-12 (reboxetine) + PlaceboAxsome TherapeuticsPhase 3
74
Solriamfetol 150 mg Oral TabletAxsome TherapeuticsPhase 1
30
AXS-12 (Reboxetine) + PlaceboAxsome TherapeuticsPhase 2
49
AXS-12 (reboxetine) + PlaceboAxsome TherapeuticsPhase 3
74